DOCSLIB.ORG

Abuse of Amphetamine, 119 Cocaine, 109 Diethylpropion, 127 Ephedrine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abuse of Amphetamine, 119 Cocaine, 109 Diethylpropion, 127 Ephedrine INDEX Abuse of 6-(2-Aminopropyl)-2,2-dimethyl-5-methoxy- amphetamine, 119 2,2-dihydrofuran, 313 cocaine, 109 Aminorex, 19,20 diethylpropion, 127 Arninoxaphen, 19 ephedrine, 128 Amitryptyline, 46,184,185 high dose, 144 AMP, see Adenosine monophosphate phenmetrazine, 124 Amphetamine, 1-98,106,111-124,258,276, Acepromazine, 47 351-359 Acetylcholine (Ach), 59, 67, 68,75-76 abuse, 120-121,352 nicotine mimics, 437 activity-structure relationship, 1-39 Acetylcholinergic transmission, 59 bacteria in, 117 N-Acetyl-3,4-dimethoxyphenethylamine, behavior due to, 41-98 274 benzedrine, 112-115, 197 N-Acetylmescaline, 274-275 inhaler, 137 Acid-head, 417 chlorinated derivatives, 9-11 Acarus calamus, 234, 284 dependence, 113, 116 Acrolein, 437 dextro-, 127, 151, 175, 178, 200 Activity-structure generalizations, 257, 272 first synthesized in 1887, 111 Additives in food, 177 metabolic pathways, 351-358 Adenosine monophosphate, cyclic, 74 murders due to, 143 Adenylate cyclase, 73-74 and narcolepsy, 148 Adrenalin, 124 and obesity, 149 hypothesis, 414 production in U_S_A_ (1958-1970), 119 Adrenochrome, 363 and psychosis, paranoid, due to, 30, 113- conversion of epinephrine to, 414 119, 121, 135, 137, 139, 277 Aguacol/a, 232 and schizophrenia, 118, 130, 137,139,141, Alcohol dehydrogenase, 342 416 Alcoholics treated with LSD, 410 and sexual maladjustment, 143 Alcoholism, 410-411 sulfate, 100,114 Aldehyde dehydrogenase, 342 use, clinical, 43 Alkaloids, 259-263 Amphetarninics, 186, 197 Alkocyphenylisopropy1amine, 298-302 Anadenanthera peregrina, 231 Alkylphenylisopropylamine, 302-313 Anesthetics, 245 Amanita muscaria, 220,222,245 Anhalonidine, 263 Amfonelic acid, 49, 50,61,74 Anhalonium lewinii, 259 Amine Animals, behavioral effects biogenic (see also separate compounds), 2-12 pretreated with drugs which modify cate­ cyclic, 344 cholaminergic neurotransmission pro­ oxidative metabolism, 348 cesses, 44-5 8 465 466 INDEX Anorexia nervosa, 18, 187-189 Bovet-Gatti profile procedure, 253, 278,302 Anticholinergics, 183 Box of Skinner, 71 Anticonvulsants in children, 201-203 Brew of witches, 224 Antidepressant, tricyclic see also separate 4-Bromo-2,5-dimethoxyamphetamine, 316 compounds, 46, 61,78,169,181,188 4-Bromo-2,5-dimethoxyphenylisopropylamine Apomorphine, 55, 56, 75 (DOB),316-317 Aptrol,302 4-Bromo-3,5-dimethoxyphenylisopropylamine, Arbol de los brujos, 225 318 Arecoline, 59 5-Bromo-2,4-dimethoxyphenylisopropylamine, Arene oxide, 341 317 Arhuaca Indians 2-Bromolysergic acid diethylamide (BOL), first to use coca, 101 252 Ariocarpus, 260 p-Bromomethamphetamine, 316 As~one,234,283,284 2-Bromo-4,5-methylenedioxyphenylisopropyl­ Assaultiveness, 143 amine, 317-318 Astrophylum, 260 4-Bromo-N-methylphenylisopropylamine, 315- Atarax, see Hydroxyzine 316 Atropa belladonna, 224 Bronchitis, chronic Atropine, 59 in smokers, 435 Austrocylindropuntia cylindrica, 260 Brugmansia, 225 Ayahuasca, 230 Brunfelsia, 233 plant extract, 258 Bufotenine, 231,414,415 Aztekium, 260 Button of peyote, 220 Butyrophenone, 47, 170 Banisteriopsis snuffs, 230, 245 B~biturate, 47, 244 Cactus (see also Peyote) Behavior aguacolla, 232 disorders of mentally ret~ded, 173-176 San Pedro, 232 hyperkinetic children, 148-149 Trichocereus pachanoi, 232 modification, 177 Caffeine, 109, 127, 178,244 peer and smoking, 429 Calea zacatechichi, 229 repetitious, 142 Cannabis, 220, 223 stereotyped, 9, 142, 152 Cannulation, push-pull, 67 tests in animals, 253 C~bamazapine(Tegretol), 202 therapy, 173 ~bamazepine(Tegretol), 202 Belladonna, 224 used in treatment for psychomotor epilepsy, Benadryl,169 202 Benzedrine, see Amphetamine C~boline,tricyclic, 258 Benzene ethaneamine, 352-359 C~bon monoxide, 437 Benzodiazepine,47 ~bon Benzoic acid, 358 oxidation of attached heteroatoms, 343-346 major urinary metabolite of amphetamine C~cinogen, 340, 346 in man, 358 C~cinogenesis, 4-5, 407 Benzoyl ecgonine, methyl ester of, 107 C~cinogenicity, 340 Benzphetamine, 18-20 Catatonia in mouse, 267 Benztropine, 61, 70, 78 Catecholamine, 44, 48, 58, 60, 62-73, 83, 84 4-Benzyloxy-3 ,5-dimethoxyphenylisopropyl- blocking, 76 amine, 299-300 in brain identified: dopamine,44 Betel nut, 244 epinephrine, 44 Biotransformation, oxidative, 351 norepinephrine, 44 Biperidin, 404 drugs which deplete, 48 Bleph~ospasm, 186 release, 58, 65-73, 83-84 BOL, see Bromolysergic acid diethylamide synthesis, 49-54, 62-63 (bromo-LSD) uptake, 46, 65-67 INDEX 467 Catecholaminergic receptor, 47-48 Cigarette (cont'd) transmission, 45-58 nicotine content of 130 brands, 428 Catechol-O-methyltransferase(COMT), 44,298 production in the U.S.A. (1886-1968),427 Catha edulis, 99 tramonium, 396 Cathidine, 100 Cimora, 232 Cathine, 100, 101 Coca (see also Cocaine), 99-105,109,220 Cathinine, 100 Coca-Cola (1888), 110 Catnip, 397 Cocaine, 66,80, 104-111,124,244 Central nervous system anesthetic, local, 105 and stimulant use, 129-148 clubs, 110 Cerebrospinal fluid (CSF), 67,72,73 Freud's interest in, 107 Cerebroventricular perfusion, 68, 80 isolation from Peruvian coco leaves, 104,107 Cereus peruvian us, 261 self-administration, 18 Channa of Hottentots, 233 Coffee, 244 CheWing khat, 99 Cohoba powder of Taino Indians, 231 Chicha, 231 Coleus blumei, 228 Children C. pumila, 228 epileptic, 201-203 Color distortion, 248 anticonvulsants for, 201-203 COMT, see Catechol.Q-methyltransferase and hyperactivity, 201 Conocybe, 225 hyperactive Coriaria thymifolia, 233 and epileptic, 201 Cresol,437 and mentally retarded, 180 Cryogenine, 229 psychotic, treatments for CSF, see Cerebrospinal fluid electroshock, 168 Cults see also separate entries megavitamin,172 jurema, 230 tranquilizer, major, 172-173 peyote, 228 p-Chloramphetamine, 9,11,19,20,42,314 San Pedro, 232 p-Chlorbenzphetamine, 20 Cyclopropane ring, 28 Chlordiazepoxide, 169, 174, 183, 184, 193, Cylert (see Pemoline) 244 Cyproheptadine, 188 p-Chlormethamphetamine, 8, 315 Cytisine, 229, 234 4-Chloro-2,5-dimethoxyphenylisopropylamine, Cynsuscanarien~, 234 320 Cytochrome-P45o electron transport system, p-Chloro-Il-methylbenzylamine, 8 338 p-Chloro-N-methylphenethylamine, 8 Cytomel, 171 p-Chlorophenylalanine,58 4-Chloro-N-methylphenylisopropylamine, 315 D, see Dopamine Chlorphentermine, 19 Dj3H, see Dopamine j3-hydroxylase 4-Chlorophenylisopropylamine, 314-315 Datura, 224, 232 Chlorpromazine, 47, 63, 136, 169, 172, 174, D. suaveolens, 230 180,188,189,195,198,199,306 Deamination, oxidative, 344 in treatment for amphetamine poisoning, 141 Decarboxylase of L-amino acid, 53 Chloprothine, 174 Dehydration, 144 Cholesterol biosynthesis, 341 Demethylation of foreign compound, 345 Chromosome, 405-407 Dependency Cigar, li ttIe on stimulant, 151 nicotine content of brands, 428 without psychosis, 116 Cigarette (see also Nicotine, Smoking) Deprenyl, 29, 30 adult incidence of smoking in the U.S.A., Depression, 146, 150-151,409-410 430 and demoralization, 151 blended, 428 withdrawal, 146 industry, 427 Desfontania spinosa, 233 lettuce, 436 Desipramine, 46, 66, 80,184 468 INDEX Detoxification via urinary excretion, 350 3,5-Dimethoxy-4(n )-propoxyphenethylamine, Dexamphetamine, 124 269 Dexedrine, 197 proscaline,269 Dexphenmet~ne,123 2,5-Dimethoxy+propylphenylisopropolamine Dextroamphetamine, see d-Amphetamine (DOPR), 310-311 N-Dialkylation, 24, 25 N,N-Dimethylmescaline, 273-274 Diazepam(Valium), 169, 181, 186, 190,244 trichocerine, 273 2,4-Dichloroamphetamine, 9 N,N-Dimethylphenethylamine, 3 Diethyldithiocarbamate, 51,53 N,N-Dimethyltryptamine, 230, 231, 258,415 Diethylpropion, 18,20,124,126-128 identical with nigerine, 231 3,4-Dihydroxyphenylacetic acid (DOPAC), 61 Diphenhydramine (Benadryl), 169, 182 DihydroxyphenyIaIanine (dopa), 44, 49, 55, Diphenylhydantoin(DPH), 182, 202 64,71,118,144,171 a,a-Diphenyl-2-piperidine ethanol, 17 Dihydroxypheny1serine (DOPS), 52 a,a-Diphenyl-4-piperidinemethanol, 17 5,6-Dihydroxytryptamine, 8 Disability 5,7-Dihydroxytryptamine, 58, 59 of learning, 196 Dilapidation of reading, 196 striking in stimulant abusers, 144 Disulfiram, 51-53 2,5-Dimethoxy-4-amylphenylisopropylamine Ditran, 396, 409 (DOAM),312-313 for treating depression, 410 2,5-Dimethoxy-4-bromopheny1ethylamine, DMA, see Dimethoxyphenylisopropylamine 271 DMPEA, see Dimethoxyphenethylamine 2,5-Dimethoxy-4-butylphenylisopropylamine DMT, see Dimethyltryptamine (DOBU),312 DOAM, see 2,5-Dimethoxy-4-amylphenyl­ 3,5-Dimethoxy-4-ethoxyphenylethylamine, isopropylamine 268-269 DOB, see 4-Bromo-2,5-dimethoxyphenyl­ escaline, 268 isopropylamine 2,5-Dimethoxy-4-ethylphenylisopropylamine DOBU, see 2,5-Dimethoxy-4-butylphenyl­ (DOET), 308-310 isopropylamine 2,5-Dimethoxy-4-iodophenethylamine, 271- DOET, see 2,5-Dimethoxy-4-ethylphenyl­ 272 isopropylamine 2,5-Dimethoxy-4-methyIamphetamine (DOM), Dolichothele, 260 30,34,42,305-306,364,365,393 DOM, see 2,5-Dimethoxy-4-methylamphet- 2,3-Dimethoxy-4,5-methy1enedioxyamphet­ amine amine,298 Dopa, see Dihydroxyphenylalanine 2,5-Dimethoxy-3,4-methylenedioxyamphet­ DOP AC, see 3,4-Dihydroxyphenylacetic acid amine, 297 Dopamine, 5-8,44,45,48-59,61-78,80-85, 2,3-Dimethoxy-4,5-methylenedioxyphenyl­ 261,267,343,413 isopropylamine (DMMDA-2), 298, 298 Dopamine ,,-hydroxylase, 44, 63, 83, 343 2,5-Dimethoxy-3,4-methy1enedioxyphenyl­ DOPR, see 2,5-Dimethoxy-4-propylphenyl- isopropylamine (DMMDA), 297-298 isopropylamine 2,6-Dimethoxy-4-methylisopropylamine, 307- OOPS, see Dihydroxyphenylserine 308 Double-conscious technique, 255 2,5-Dimethoxy-4-methylphenethylamine, 270- DPH, see Diphenylhydantoin 271 Dreams, frightening, 189 2,5-Dimethoxy-4-methylphenylisopropylainine, Drug 281-282,304-307 addiction, 101 3,4-Dimethoxyphenylethylamine
Load more

Recommended publications
  • Scientific Assessment of Ephedra Species (Ephedra Spp.)
    Annex 3 Ref. Ares(2010)892815 – 02/12/2010 Recognising risks – Protecting Health Federal Institute for Risk Assessment Annex 2 to 5-3539-02-5591315 Scientific assessment of Ephedra species (Ephedra spp.) Purpose of assessment The Federal Office of Consumer Protection and Food Safety (BVL), in collaboration with the ALS working party on dietary foods, nutrition and classification issues, has compiled a hit list of 10 substances, the consumption of which may pose a health risk. These plants, which include Ephedra species (Ephedra L.) and preparations made from them, contain substances with a strong pharmacological and/or psychoactive effect. The Federal Ministry of Food, Agriculture and Consumer Protection has already asked the EU Commission to start the procedure under Article 8 of Regulation (EC) No 1925/2006 for these plants and preparations, for the purpose of including them in one of the three lists in Annex III. The assessment applies to ephedra alkaloid-containing ephedra haulm. The risk assessment of the plants was carried out on the basis of the Guidance on Safety Assessment of botanicals and botanical preparations intended for use as ingredients in food supplements published by the EFSA1 and the BfR guidelines on health assessments2. Result We know that ingestion of ephedra alkaloid-containing Ephedra haulm represents a risk from medicinal use in the USA and from the fact that it has now been banned as a food supplement in the USA. Serious unwanted and sometimes life-threatening side effects are associated with the ingestion of food supplements containing ephedra alkaloids. Due to the risks described, we would recommend that ephedra alkaloid-containing Ephedra haulm be classified in List A of Annex III to Regulation (EC) No 1925/2006.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • KHAT Latest Revision: June 11, 2005
    KHAT Latest Revision: June 11, 2005 O CH3 NH2 Cathinone OH CH3 NH2 Cathine N CH3 H3C N 3,6-dimethyl-2,5-diphenylpyrazine (dimer of Cathinone) 1. SYNONYMS CFR: Cathinone Cathine CAS #: Cathinone Hydrochloride: 71031-15-7 Cathine Hydrochloride: 2153-98-2 Cathine Base: 492-39-7 Other Names: Catha edulis Kat Mutsawhari Mutsawari Mdimamadzi Musitate Mirungi Miraa Ol meraa Tumayot Liruti Ikwa Arabian Tea 2. CHEMICAL AND PHYSICAL DATA Khat is used as a stimulant or as a medicine in parts of Africa and the Arabian Peninsula. The plant is thought to have been in cultivation before the coffee plant; historical references date the use of the plant to the fourteenth century. Peter Forsskal, a physician and botanist, collected khat specimens in an expedition organized by the King of Denmark in the eighteenth century. Forsskal assigned the name Catha edulis to the plant. The effects produced by the drug include excitation, hypersensitivity, anorexia, insomnia, euphoria, increased respiration, and hyperthermia. These effects closely parallel the effects of d-amphetamine. Khat is a bush or tree that grows naturally in the humid mountainous regions (elevations of 5000 to 6500 feet) of East and South Africa. The trees can grow naturally to over 60 ft; however, cultivated khat trees are pruned and their height to kept to approximately 16 feet. Khat also grows to a height of 3 feet as a small bush in arid regions. Like opium, the alkaloid content of khat will vary with the soil, climatic conditions, and cultivation. Khat belongs to the genus Catha edulis. It is recognized that the genus consists of only one species; however, the plant exhibits extreme polymorphism.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Incorporating Parents in the Anti-Doping Fight: a Test of the Viability of a Parent-Based Prevention Program
    1 Social Science Research Fund: Incorporating Parents in the Anti-Doping Fight: A Test of the Viability of a Parent-Based Prevention Program Final Report Submitted to: World Anti-Doping Agency Prepared by: Tonya Dodge, Ph.D. Skidmore College* *Investigator will be moving to The George Washington University Contact Information: Tonya Dodge, Ph.D. The George Washington University Department of psychology 2125 G Street, NW Washington, DC 20052 e-mail: [email protected] 2 Table of Contents Executive Summary.............................................................................................................................................. 3 Background ............................................................................................................................................................. 5 Interventions Targeting AS Use ....................................................................................................................... 6 Building Parent-Based Interventions: Considerations ........................................................................... 7 A Parent-Based Framework to Prevent AS and NS Use ......................................................................... 9 Study Aims ............................................................................................................................................................ 10 Methods ................................................................................................................................................................
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]